1、novotech-DECEMBER 19,2023Candidiasis Global Clinical Trial LandscapeAPAC contrib-uted 60%of candidia-sis trials,led by Mainland ChinaThe US and Europe con-ducted 30%of can-didiasis trials,with Germany and Belgium in the leadROW con-ducted 5%of the global candi-diasis trialsAPAC shows shorter recruit

2、ment durations and faster recruitment rates compared to Europe and the US60%30%5%Candidiasis is an oppor-tunistic infection that mostly afects the oral cavity and repro-ductive organsMost common secondary infection in immuno-compro-mised individualsAstellas Pharmas Mycamine is a marketed leader for

3、invasive candidiasisBasilea Pharmaceuticas Cresemba,currently in Phase III,represents a promising candidate for the treatment of candidemia,disseminated candidiasis,and esophageal candidiasisDidyouknow?Brazil and Colombia reported the highest incidence rates among all the countriesIn Europe,Hungary

4、reported a relatively higher incidence of candidiasisThe United States reported higher incidence rates of candidiasis,whereas Canada reported the lowest ratesIn Asia,Thailand reported a relatively high incidence,indicating a substantial burden,while Malaysia had a lower incidence rate of candidiasis

5、The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech

6、except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribut